Saturday, October 19, 2013

Ramirez late addition to Dodgers lineup


ST. LOUIS (AP) — Hanley Ramirez was a late addition to the Los Angeles Dodgers lineup, batting cleanup for Game 6 of the NL championship series Friday night.

Manager Don Mattingly said in his pregame news conference that there was a slight chance Ramirez could start, and the change was announced less than a half-hour before the first pitch. Ramirez has been hindered by a rib injury he sustained when he was hit by a pitch in the series opener.

Just before the announcement, Ramirez was on the field playing catch. He entered with a .167 average in the NLCS.

Mattingly's original lineup had Nick Punto playing shortstop and batting eighth and Yasiel Puig batting cleanup. Puig moved to sixth in the revised lineup, while Juan Uribe and A.J. Ellis each moved down one spot to seventh and eighth.

Jon Jay, slumping at the field and at the plate, was not in the St. Louis Cardinals' batting order against Clayton Kershaw. St. Louis led the best-of-seven series 3-2.

Manager Mike Matheny noted he often loads his lineup with right-handed hitters against difficult lefties. Although the Cardinals were 3-0 in three starts against Kershaw coming in, they were just 19-23 against left-handers.

Kershaw held left-handed hitters to a .165 average in the regular season. He allowed an unearned run over six innings in a 1-0 Game 1 loss.

"It's no secret how effective Kershaw has been against left-handed hitters and he's a tough assignment," Matheny said. "Sometimes you can put another piece in there and hopefully get a little jump."

"I expected he'd be a little better," Mattingly said. "Maybe with the lack of activity it's gotten stiffer and tighter. He feels worse today than he did yesterday."

Shane Robinson got his first start of the postseason in place of Jay, batting seventh and playing center field. Robinson's pinch homer in Game 4 was his first hit of this postseason and Matheny noted "he plays a plus defense."

Jay was batting .176 (3 for 17) in the NLCS. He failed to take charge on a catchable fly ball by Mark Ellis and the ball fell in for a double that keyed the Dodgers' go-ahead rally in Game 3.

Source: http://news.yahoo.com/ramirez-addition-dodgers-lineup-003105782--spt.html
Similar Articles: carrie   today show   us open   Asap Rocky   Teen Beach Movie  

Friday, October 18, 2013

Why Is There No Male Birth Control Pill?

Why Is There No Male Birth Control Pill?

Bet you didn't have this marked on your calendar: today is World Vasectomy Day, a holiday celebrated not with parades or fireworks, but with the delicate snip of two tiny tubes. But is such a largely permanent step really our only male birth control option? Where's the male version of the pill?

Read more...


    






Source: http://feeds.gawker.com/~r/gizmodo/full/~3/bljxfdULIaw/where-is-the-male-birth-control-pill-1447917796
Tags: Eminem Rap God   act   Jacoby Jones   Brynn Cameron   Rosy Esparza  

'Castle' Creator, Michael De Luca Updating Raymond Chandler's Philip Marlowe for ABC




CAA; Getty Images


Terri Edda Miller and Andrew Marlowe with Michael De Luca



Castle creator Andrew Marlowe is bringing Raymond Chandler's famed detective Philip Marlowe back to life.



The showrunner behind the Nathan Fillion starrer is teaming with Castle writer/consulting producer Terri Edda Miller and prolific producer Michael De Luca (The Social Network) for an untitled Philip Marlowe drama set up at ABC with a script commitment.


The drama is described as a smart, sexy and stylish update of Chandler's timeless character. It follows the investigations of the wisecracking, edgy and rugged private detective, Philip Marlowe, as he navigates the morally complicated world of today's Los Angeles, where the California sun casts long and dangerous shadows, and where true love can be more difficult to find that justice.


PHOTOS: Faces of Fall TV 2013


Married duo Marlowe and Miller will pen the script and executive produce via their MilMar Pictures banner for ABC Studios and Michael De Luca Productions.


Chandler's Philip Marlowe first appeared in Chandler's 1939 work The Big Sleep and went on to appear in subsequent pulp magazines, short stories and radio programs on CBS, and later NBC. The character previously appeared on TV in Philip Marlowe, Private Eye, a British mystery drama that aired on ITV in the U.K. and stateside on HBO in the 1980s. The series starring Powers Boothe was the first drama produced for HBO. ABC previously took on the character from 1959-60 with a half-hour crime series starring Philip Carey as Marlowe. The series was canceled after one season of 26 episodes. The BBC revived the radio series in 2011 with a series of Chandler's works.


Actors who have played the famed detective include Van Heflin (NBC Radio), Robert Montgomery (CBS Radio), Dick Powell (CBS Radio), Gerald Mohr (CBS Radio), Ed Bishop (BBC Radio), Danny Glover (Showtime) and James Caan (HBO's Poodle Springs movie).


For De Luca, the Philip Marlowe drama marks his latest high-profile small-screen project. The two-time Oscar winner (Social Network, Moneyball) also serves as an exec producer on Frank Darabont's upcoming TNT drama, Mob City, which debuts in December. He's prepping a remake of Shogun, a limited series for Fox, as well as a Sutton adaptation for FX with Alexander Payne; Syfy's Childhood's End; and Columbine at Lifetime, among other works.


PHOTOS: Broadcast TV's Returning Shows 2013-14


De Luca is repped by CAA and Gang Tyre. Marlowe is with CAA, Management 360 and Lichter Grossman. Miller is repped by CAA, Field Entertainment and Lichter Grossman. The Raymond Chandler estate is repped by CAA, the Ed Victor Agency in London and Greenberg Taurig.


In its sixth season, Castle remains a valuable property for ABC on Mondays. Its fifth season ranked as ABC's most-watched scripted drama among total viewers, averaging more than 12 million over 28 telecasts. 


The Philip Marlowe drama also comes as NBC rebooted Ironside, a remake of the Raymond Burr detective drama, which ran for eight seasons and nearly 200 episodes from 1967-75. The Blair Underwood-fronted drama has not fared well this fall in its Wednesdays at 10 p.m. slot, averaging a 1.2 in the key adults 18-49 demographic.


At the same time, CBS is remaking The Cisco Kid and Love, American Style, as well as NBC's new take on Remington Steele this development season.


E-mail: Lesley.Goldberg@THR.com
Twitter: @Snoodit



Source: http://feedproxy.google.com/~r/live_feed/~3/sWIhU7JxCFU/story01.htm
Tags: Ed Sheeran   downton abbey   nfl   Vma Miley Cyrus   david ortiz  

Vaccine confers long-term protection against cholera

Vaccine confers long-term protection against cholera


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

16-Oct-2013



[


| E-mail



| Share Share

]

Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute



First time an oral cholera vaccine is proven to provide sustained protection for five years against cholera



A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65% over a five-year period. The landmark study was a collaboration between scientists from the International Vaccine Institute (IVI) an international organization based in Seoul, and the National Institute of Cholera and Enteric Diseases, (NICED), an institute under the Indian Council of Medical Research (ICMR) of India's Ministry of Health and Family Welfare.


Cholera is a potentially deadly infectious disease that causes profuse, dehydrating diarrhea in children and adults. It is spread through ingestion of contaminated water or food and is commonly found in developing countries that have limited access to clean water and sanitation. There are about 2.8 million cases and 91,000 deaths each year from cholera, mostly in Africa and South Asia.


The oral cholera vaccine (OCV) contains strains of killed cholera bacteria that have been previously shown to be safe in humans and is administered through a two-dose regimen. The vaccine was specifically developed for use in developing countries through a public-private partnership led by IVI with support from the Republic of Korea, Sweden, and the Bill & Melinda Gates Foundation. The partnership involved Shantha Biotechnics (part of the Sanofi group) based in Hyderabad, India; VaBiotech, a state-owned vaccine manufacturer located in Hanoi, Vietnam; and the University of Gothenburg in Sweden. The vaccine, which is produced by Shantha Biotechnics in India and licensed as Shanchol, was prequalified by the World Health Organization (WHO) in September 2011.


A Phase III clinical trial was jointly conducted by IVI and NICED in Kolkata, India in 2006 to assess the efficacy of the vaccine. More than 30,000 volunteers from one year old and up were enrolled in the study. A placebo group with a similar number of volunteers was also included.


Previous results from this study had shown that the vaccine provided 66% protection over a three-year period, and the new result shows that such protection is sustained for two additional years. Since vaccine protection does not wane over time, the study has important practical implications in terms of vaccination cost and vaccination strategies in developing countries.


"The study results suggest that this vaccine will protect persons at risk of severe cholera for five years," said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI and co-author of the study. "With protection sustained for five years, we will be able to provide greater benefits to the poor at reduced costs."


Furthermore, the study confirms the use of the vaccine as a powerful and effective tool to prevent and control cholera. "The vaccine is safe, easy to administer, cost effective, and provides protection for up to five years," said Dr. Christian Loucq, IVI's Director General. "The use of the vaccine, combined with other control measures, will make it more feasible for developing countries afflicted by cholera to control a disease that plagues millions of people every year."



The vaccine has already been used to combat outbreaks in Haiti and Guinea, and has been deployed for large-scale use in Bangladesh and Odisha state, India.


###


About IVI

The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.




[ Back to EurekAlert! ]

[


| E-mail



| Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Vaccine confers long-term protection against cholera


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

16-Oct-2013



[


| E-mail



| Share Share

]

Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute



First time an oral cholera vaccine is proven to provide sustained protection for five years against cholera



A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65% over a five-year period. The landmark study was a collaboration between scientists from the International Vaccine Institute (IVI) an international organization based in Seoul, and the National Institute of Cholera and Enteric Diseases, (NICED), an institute under the Indian Council of Medical Research (ICMR) of India's Ministry of Health and Family Welfare.


Cholera is a potentially deadly infectious disease that causes profuse, dehydrating diarrhea in children and adults. It is spread through ingestion of contaminated water or food and is commonly found in developing countries that have limited access to clean water and sanitation. There are about 2.8 million cases and 91,000 deaths each year from cholera, mostly in Africa and South Asia.


The oral cholera vaccine (OCV) contains strains of killed cholera bacteria that have been previously shown to be safe in humans and is administered through a two-dose regimen. The vaccine was specifically developed for use in developing countries through a public-private partnership led by IVI with support from the Republic of Korea, Sweden, and the Bill & Melinda Gates Foundation. The partnership involved Shantha Biotechnics (part of the Sanofi group) based in Hyderabad, India; VaBiotech, a state-owned vaccine manufacturer located in Hanoi, Vietnam; and the University of Gothenburg in Sweden. The vaccine, which is produced by Shantha Biotechnics in India and licensed as Shanchol, was prequalified by the World Health Organization (WHO) in September 2011.


A Phase III clinical trial was jointly conducted by IVI and NICED in Kolkata, India in 2006 to assess the efficacy of the vaccine. More than 30,000 volunteers from one year old and up were enrolled in the study. A placebo group with a similar number of volunteers was also included.


Previous results from this study had shown that the vaccine provided 66% protection over a three-year period, and the new result shows that such protection is sustained for two additional years. Since vaccine protection does not wane over time, the study has important practical implications in terms of vaccination cost and vaccination strategies in developing countries.


"The study results suggest that this vaccine will protect persons at risk of severe cholera for five years," said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI and co-author of the study. "With protection sustained for five years, we will be able to provide greater benefits to the poor at reduced costs."


Furthermore, the study confirms the use of the vaccine as a powerful and effective tool to prevent and control cholera. "The vaccine is safe, easy to administer, cost effective, and provides protection for up to five years," said Dr. Christian Loucq, IVI's Director General. "The use of the vaccine, combined with other control measures, will make it more feasible for developing countries afflicted by cholera to control a disease that plagues millions of people every year."



The vaccine has already been used to combat outbreaks in Haiti and Guinea, and has been deployed for large-scale use in Bangladesh and Odisha state, India.


###


About IVI

The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.




[ Back to EurekAlert! ]

[


| E-mail



| Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-10/ivi-vcl101613.php
Tags: stenographer   Dallas Latos   eagles   Léon Foucault   harry potter  

Hillary Clinton, Ron Perelman Honored at 2013 Elton John AIDS Foundation Benefit



Source: http://feedproxy.google.com/~r/thr/business/~3/YvsYyvpHuc4/story01.htm
Category: charlie hunnam   freedom tower   pharrell   taylor swift   The Conjuring  

Oxford's Library Chooses Its First New Chair Design Since 1936

Oxford's Library Chooses Its First New Chair Design Since 1936


Oxford's Bodleian library—aka the Bod—is one of England's largest libraries, a 414-year-old research hub steeped in tradition and history. For example, only three types of chair have ever been designed for use inside its walls. Until now, that is: According to Co.Design, the library has chosen a fourth design to replace its older models.

Read more...

Source: http://gizmodo.com/oxfords-library-chooses-its-first-new-chair-design-sin-1445918510
Related Topics: ny giants   liam hemsworth   lamar odom   us open tennis   Demi Lovato  

Thursday, October 17, 2013

First look: Ladies of 'Grimm' are getting tough

TV











4 hours ago

Image: Grimm

Scott Green / NBC

Juliette (Bitsie Tulloch, left) and Rosalee (Bree Turner) aren't standing idly by when "Grimm" returns next Friday.

The guys of NBC's fairy-tale crime drama "Grimm" usually find themselves at the center of most of the action, but the ladies aren't slouches either.

When the show returns on Oct. 25, Juliette (Bitsie Tulloch), Adalind (Claire Coffee) and Rosalee (Bree Turner) aren't going to be standing around and looking pretty, they're going to be right in the thick of things. After all, Nick (David Giuntoli) has been captured (and turned into a zombie), and it looks like Juliette and Rosalee will have to combine their strengths to help find him. 

Meanwhile, Adalind, the former Hexenbiest, is still using her charm and her smarts to try to regain her powers.

A video called "The Ladies of Grimm" that NBC is sharing first with TODAY shows just how big a role the women will be playing in the new season.

"They're very self-assured, they know what they want," teases Coffee in the clip.

"I think you're going to see a lot more of that in season three," Tulloch adds of the female action. The actress also noted that Juliette is no damsel in distress. "It's been alluded to that she's kind of a bad ass!"

"It just presents women who are strong, women who are smart, and women who are taking action," Coffee says in the video as scenes of the ladies taking tough situations into their own hands roll by. "The women of 'Grimm' kick ass!"

"Grimm" season three premieres Oct. 25 at 9 p.m. on NBC.








Source: http://www.today.com/entertainment/move-over-boys-ladies-grimm-are-getting-tough-8C11407362
Category: foxnews   Alexian Lien